JP2010509234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509234A5 JP2010509234A5 JP2009535486A JP2009535486A JP2010509234A5 JP 2010509234 A5 JP2010509234 A5 JP 2010509234A5 JP 2009535486 A JP2009535486 A JP 2009535486A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2010509234 A5 JP2010509234 A5 JP 2010509234A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- antibody
- patient
- interleukin
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 31
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 31
- 230000003211 malignant effect Effects 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 64
- 230000027455 binding Effects 0.000 description 15
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 13
- 206010066476 Haematological malignancy Diseases 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000000013 Chemokine CCL3 Human genes 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 102000013462 Interleukin-12 Human genes 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 8
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 8
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 8
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 229940117681 interleukin-12 Drugs 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 229940096397 interleukin-8 Drugs 0.000 description 8
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108700012434 CCL3 Proteins 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 229940076144 interleukin-10 Drugs 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000007541 Preleukemia Diseases 0.000 description 2
- 208000009527 Refractory anemia Diseases 0.000 description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85653006P | 2006-11-02 | 2006-11-02 | |
| US87443906P | 2006-12-11 | 2006-12-11 | |
| US94302107P | 2007-06-08 | 2007-06-08 | |
| PCT/US2007/083508 WO2008058021A2 (en) | 2006-11-02 | 2007-11-02 | Methods of treating neoplastic, autoimmune and inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509234A JP2010509234A (ja) | 2010-03-25 |
| JP2010509234A5 true JP2010509234A5 (https=) | 2010-12-16 |
Family
ID=39365271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535486A Pending JP2010509234A (ja) | 2006-11-02 | 2007-11-02 | 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20110038856A1 (https=) |
| EP (1) | EP2084527A4 (https=) |
| JP (1) | JP2010509234A (https=) |
| AU (1) | AU2007317333A1 (https=) |
| CA (1) | CA2667808A1 (https=) |
| WO (1) | WO2008058021A2 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| AU2007317333A1 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| ES2542152T3 (es) | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| HUE032563T2 (en) | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| CA2722184A1 (en) | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| WO2011022861A1 (zh) * | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| CA2773579C (en) | 2009-09-10 | 2019-01-15 | Kyowa Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4) |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| GB201016864D0 (en) | 2010-10-06 | 2010-11-17 | Univ Aston | Therapeutic methods |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| AU2013323472B2 (en) | 2012-09-28 | 2018-07-05 | Ellis KLINE | Glycosidase regimen for treatment of infectious disease |
| AU2014207429B2 (en) * | 2013-01-18 | 2018-11-01 | Ellis KLINE | Selective glycosidase regimen for immune programming and treatment of cancer |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| AR097648A1 (es) * | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| MX2017015380A (es) | 2015-05-29 | 2018-03-28 | Amphivena Therapeutics Inc | Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33. |
| JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| JP7497953B2 (ja) | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| WO2017210621A1 (en) | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| WO2018112407A1 (en) | 2016-12-15 | 2018-06-21 | Duke University | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |
| KR102733407B1 (ko) | 2017-08-03 | 2024-11-21 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
| US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| MX2021002299A (es) | 2018-08-31 | 2021-04-28 | Alector Llc | Anticuerpos de anti-cd33 y metodos para usarlos. |
| EP3863644A4 (en) * | 2018-10-12 | 2022-10-05 | Jeanmarie Guenot | CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| US20220331247A1 (en) * | 2019-09-23 | 2022-10-20 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec | Polymeric micelle, methods of production and uses thereof |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022075756A1 (ko) * | 2020-10-08 | 2022-04-14 | 주식회사 큐롬바이오사이언스 | 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물 |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1991009058A1 (en) * | 1989-12-14 | 1991-06-27 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| US6007814A (en) * | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| WO1998006733A1 (en) * | 1996-08-09 | 1998-02-19 | Human Genome Sciences, Inc. | Nucleotide sequence encoding the cd33-like protein |
| US6653104B2 (en) * | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US7194554B1 (en) * | 1998-12-08 | 2007-03-20 | Nomadix, Inc. | Systems and methods for providing dynamic network authorization authentication and accounting |
| EP1309627B1 (en) * | 2000-08-08 | 2009-09-30 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody |
| AU2002348178A1 (en) * | 2002-11-06 | 2004-06-03 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| BR0316101A (pt) * | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| AU2005306325A1 (en) * | 2004-11-22 | 2006-05-26 | King Pharmaceuticals Research & Development Inc. | Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists |
| WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| AU2007317333A1 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
-
2007
- 2007-11-02 AU AU2007317333A patent/AU2007317333A1/en not_active Abandoned
- 2007-11-02 WO PCT/US2007/083508 patent/WO2008058021A2/en not_active Ceased
- 2007-11-02 JP JP2009535486A patent/JP2010509234A/ja active Pending
- 2007-11-02 US US12/513,313 patent/US20110038856A1/en not_active Abandoned
- 2007-11-02 EP EP07863851A patent/EP2084527A4/en not_active Withdrawn
- 2007-11-02 CA CA002667808A patent/CA2667808A1/en not_active Abandoned
-
2008
- 2008-04-11 US US12/101,785 patent/US7695716B2/en active Active
-
2010
- 2010-02-26 US US12/714,235 patent/US20100215653A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509234A5 (https=) | ||
| Propper et al. | Harnessing cytokines and chemokines for cancer therapy | |
| Atkins | Interleukin-2: clinical applications | |
| Barton et al. | Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model | |
| Szekanecz et al. | Macrophages and their products in rheumatoid arthritis | |
| Moldawer et al. | The role of cytokines in cancer cachexia | |
| Bukowski | Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin‐2 | |
| Nemunaitis et al. | Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation | |
| Couriel et al. | Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation | |
| Weisbart et al. | Physiology of granulocyte and macrophage colony-stimulating factors in host defense. | |
| JP2006514024A5 (https=) | ||
| Hasselbalch et al. | New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms | |
| Engles et al. | Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia–reperfusion injury | |
| Kremer et al. | lnterleukin-1-6 and tumor necrosis Factor-α release is down-regulated in whole blood from septic patients | |
| Lentsch et al. | Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2 | |
| Higuchi et al. | Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors | |
| Tsimberidou et al. | TNF-α targeted therapeutic approaches in patients with hematologic malignancies | |
| Koumakis et al. | Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide | |
| Franks et al. | Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival | |
| Xing et al. | Consideration of cytokines as therapeutics agents or targets | |
| Brok et al. | IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells | |
| Perez et al. | Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study | |
| Miles et al. | Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2 | |
| Steinhauser et al. | New frontiers in cytokine involvement during experimental sepsis | |
| Van Montfrans et al. | Immunotherapy of Crohn′ s disease |